Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Market Capitalization on January 14, 2025: USD 2.39 B

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Market Capitalization is USD 2.39 B on January 14, 2025, a 62.41% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. 52-week high Market Capitalization is USD 3.11 B on October 25, 2024, which is 29.79% above the current Market Capitalization.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. 52-week low Market Capitalization is USD 995.52 M on February 05, 2024, which is -58.43% below the current Market Capitalization.
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. average Market Capitalization for the last 52 weeks is USD 1.67 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
Shenzhen Stock Exchange: 300255.SZ

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

CEO Ms. Hao Cai
IPO Date Aug. 19, 2011
Location China
Headquarters Zhengding County High-tech Ind Dev Zone
Employees 1,410
Sector Health Care
Industries
Description

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China. Its products include crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadra Heparin calcium raw materials, nadroparin calcium injections, and dalteparin sodium raw materials and injections. The company was founded in 2000 and is based in Shijiazhuang, China.

StockViz Staff

January 15, 2025

Any question? Send us an email